EI-1071 – Patient Worthy

Sourced from: James Heilman, MD / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

ICYMI: EI-1071 for IPF Earns Orphan Drug Status

Post author:Jessica Lynn
Post published:September 14, 2022
Post category:Idiopathic Pulmonary Fibrosis

According to an August 2022 news release from biotechnology company Elixiron Immunotherapeutics (“Elixiron”), EI-1071, a therapy for patients with idiopathic pulmonary fibrosis (IPF), recently earned Orphan Drug designation from…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More